drugset / Trial / NCT03635593

Cannabis Oil for Chronic Non-Cancer Pain Treatment

NCT03635593

Phase 2 Unknown 309 enrolled Hamilton Health Sciences Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Cannabis is being prescribed medically for chronic non-cancer pain despite limited evidence whether or not it works to reduce average pain in patients with chronic non-cancer pain. The cannabis plant (Cannabis sativa, Cannabis indica) consists of several hundred compounds of which, approximately 70 of which are thought to be active. The two active cannabinoids of interest in this trial are tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD). The goal of this trial is to determine whether CBD or CBD+THC reduces the average pain in participants with chronic non-cancer pain. The investigators also aim to determine whether CBD or CBD+THC is associated with a reduction in pain severity, pain interference, anxiety, depression, insomnia, opioids and use of benzodiazepines, analgesics, antidepressants, anxiolytics, or hypnotics amongst chronic non-cancer pain patients or an increase in physical functioning, physical health related role limitations, social functioning, mental functioning.

Timeline

Start
2019-01-01
Primary completion
2021-01-30
Completion
2021-01-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cannabidiol Other / unclassified 5 mg
Comparator Cannabidiol Other / unclassified 10 mg
Subject Dronabinol Other / unclassified 5 mg

Indications